Immunology & Inflammation

Nrf2 Activator-10 (Compound AI-1) acts as a PI3K-dependent inducer of the antioxidant response element (ARE), with an EC50 value of 2.7 μM, effectively activating Nrf2. By modifying Keap1 and inhibiting the Cul3-Keap1 ubiquitin ligase complex, Nrf2 Activator-10 enhances Nrf2 transcription and promotes cellular defense mechanisms. This compound is particularly valuable for research focused on oxidative stress and cytoprotection, demonstrating protective effects against H2O2-induced apoptosis.

(-)-Pinoresinol is a plant-derived tetrahydrofuran lignan that serves as an anti-inflammatory agent through the inhibition of α-glucosidase. This compound exhibits hypoglycemic properties and demonstrates chemopreventive potential by inducing apoptosis and causing G2/M phase cell cycle arrest. Its biological activities make it a valuable tool for research in inflammation and metabolic disorders.

Taurodeoxycholate-d6 sodium is an anionic detergent derived from bile salts, functioning primarily as an anti-inflammatory agent. This compound promotes the isolation of membrane proteins, particularly in the inner mitochondrial membrane, making it essential for studies in cellular biology. Furthermore, Taurodeoxycholate-d6 demonstrates notable anti-inflammatory and neuroprotective properties, positioning it as a valuable tool for research applications focused on inflammation and neuroprotection pathways.

Lactucin is a recognized anti-inflammatory agent that promotes apoptosis in cancer cells. Additionally, it exhibits analgesic, anticancer, and antimalarial properties, making it a versatile compound for various biological research applications. Its multifaceted activity provides valuable insights into potential therapeutic interventions for inflammatory diseases and cancer.

Isoangustone A is an effective anticancer and anti-inflammatory agent that promotes apoptosis and autophagic cell death in cancer cells. This compound is of interest for research applications aimed at understanding cancer biology and developing potential therapeutic strategies. Its dual action highlights its relevance in the study of cancer progression and inflammation-mediated diseases.

Lenalidomide-d5 is a stable isotope-labeled derivative of Lenalidomide, an immunomodulatory compound that functions as a molecular glue. By acting as a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and subsequent degradation of the transcription factors IKZF1 and IKZF3. Lenalidomide-d5 is pivotal for research in cancer biology, particularly for investigating the mechanisms of action in mature B-cell lymphomas, including multiple myeloma, and for studying its effects on cytokine release from T cells.

HL001 is an oral small molecule inhibitor targeting Cyclophilin A (CypA) and acting as a receptor antagonist for Lysophosphatidic acid 1 (LPA1). This compound induces cell cycle arrest and apoptosis in tumor cells via p53 stabilization, achieved by down-regulating G3BP1 and promoting reactive oxygen species production and DNA damage. HL001 disrupts the MDM2-p53-72R interaction in a CypA-dependent manner, demonstrating significant antitumor activity. Additionally, HL001 serves as a valuable tool in the investigation of pulmonary fibrosis.

VAS 3947 is a selective inhibitor of NADPH oxidase (NOX), demonstrating significant antiplatelet activity. In addition to its role as an NOX inhibitor, VAS 3947 induces apoptosis through the activation of the unfolded protein response (UPR), primarily driven by protein aggregation and misfolding. This compound is valuable for research focused on oxidative stress and its implications in cardiovascular diseases.

TFAP2β modulator-1 is a potent modulator of the transcription factor TFAP2β, promoting its condensation through the induction of conformational changes within its intrinsically disordered region. This compound exhibits significant anti-tumor activity by inducing apoptosis in esophageal squamous cell carcinoma (ESCC) cells, as well as in relevant mouse models and organoids. TFAP2β modulator-1 serves as a valuable tool for investigating the role of TFAP2β in ESCC research and therapeutic development.

Panduratin A is a potent inhibitor of the NF-κB signaling pathway, recognized for its significant anti-inflammatory and antioxidant properties. It demonstrates protective effects against nephrotoxicity induced by Colistin, primarily by mitigating oxidative stress and enhancing mitochondrial function. Additionally, Panduratin A activates autophagy through an AMPK-dependent mechanism and exhibits potential anti-tuberculosis and antiviral activities by inhibiting the methyltransferase of SARS-CoV-2. These diverse biological activities make Panduratin A a valuable tool in various areas of research, including inflammation, cellular stress responses, and infectious diseases.

Thalidomide-4-O-C6-NH2 TFA is a synthetic E3 ligase ligand-linker conjugate designed for use in targeted protein degradation applications. This compound plays a critical role in the PROTAC dTAG-13, facilitating the selective degradation of FKBP12F36V and BET proteins. Its unique structural features allow for efficient recruitment of E3 ligases, making it a valuable tool in cellular studies of protein regulation and degradation pathways.

MK-886 sodium salt is a potent inhibitor of the 5-lipoxygenase-activating protein (FLAP), exhibiting an IC50 of 30 nM. It effectively inhibits leukotriene biosynthesis with IC50 values of 3 nM in intact leukocytes and 1.1 μM in human whole blood. Additionally, MK-886 acts as a non-competitive antagonist of PPARα and can induce apoptosis, making it a valuable tool for research in inflammatory diseases and apoptosis pathways.

Ketorolac hemicalcium is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective cyclooxygenase (COX) inhibitor, exhibiting IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is utilized in research related to allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain, as well as for its potential applications in cancer research due to its role as a DDX3 inhibitor.

Nrf2 activator-11 is a potent Nrf2 activator that demonstrates blood-brain barrier permeability. This compound exhibits significant biological activities, including antioxidant, anti-inflammatory, anti-ferroptotic, and anti-apoptotic effects. Nrf2 activator-11 is particularly valuable for research involving cerebral ischemia-reperfusion injury models, providing insights into neuroprotective mechanisms and therapeutic interventions.

Metamizole magnesium is an orally active cyclooxygenase (COX) inhibitor known for its key roles in reducing inflammation and pain. It exhibits significant anti-inflammatory and antioxidant activities, along with the ability to inhibit cell proliferation and promote apoptosis. Due to its antipyretic and analgesic properties, Metamizole magnesium is commonly utilized in various research applications aimed at investigating pain mechanisms and inflammatory responses.

Stephanine ((-)-Stephanine) is an isoquinoline aporphine-type alkaloid known for its anti-inflammatory properties. It induces apoptosis via the reversal of mitotic exit, demonstrating significant antiplasmodial activity. This compound is valuable for research applications related to gastrointestinal disorders, inflammatory conditions such as arthritis, and various cancer types.

Topo I/COX-2-IN-1 is an inhibitor of both Topoisomerase I and Cyclooxygenase-2 (COX-2). It demonstrates significant biological activity, with IC50 values of 0.24 μM for COX-2 and 4.42 μM for Topo I. This compound effectively induces apoptosis and inhibits the migration of cancer cells, showcasing potential applications in cancer research and therapy.

Topo I/COX-2-IN-2 is a potent dual-target inhibitor of Topoisomerase I (Topo I) and Cyclooxygenase-2 (COX-2), exhibiting inhibitory concentrations (IC50) of 0.90 μM and 2.31 μM, respectively. This compound induces apoptosis in cancer cells via the mitochondrial pathway, making it a valuable agent for research in cancer therapeutics and cell death mechanisms. Its dual activity supports investigations into the interplay between topoisomerase inhibition and inflammatory pathways in cancer progression.

PDIC-NN dimethanesulfonate is a potent STING activator known for its anticancer properties. It enhances the stability and levels of endogenous cyclic dinucleotides (CDNs), triggering a reactive oxygen species (ROS) burst that damages mitochondria, thereby inducing apoptosis and inhibiting DNA replication. By activating the cGAS-STING signaling pathway, PDIC-NN dimethanesulfonate boosts the immunogenicity of tumor cells and stimulates a robust innate immune response, making it a valuable reagent for cancer immunotherapy research.

OSU-03013 is a Celecoxib analog that targets multiple pathways involved in cancer progression. It promotes apoptosis while enhancing E-cadherin expression and reduces β-catenin, c-myc, Wnt1, and N-cadherin levels. By inhibiting cell migration and invasion, OSU-03013 effectively regulates Wnt and mTOR signaling, leading to decreased proliferation of colon cancer cells. This compound is suitable for research focused on colon cancer and its underlying mechanisms.

Polyinosinic-polycytidylic acid sodium is a synthetic analogue of double-stranded RNA and acts as an agonist for toll-like receptor 3 (TLR3) and RIG-I-like receptors. It serves as a potent immunomodulator, enhancing both innate and adaptive immune responses, making it valuable for vaccine development. Additionally, Poly(I:C) sodium can influence the tumor microenvironment and directly induce apoptosis in cancer cells, thus providing significant potential in cancer research and therapy.

Dextran sulfate sodium salt (DSS, MW 5000) primarily functions as a complement inhibitor, derived from a polymer of dehydrated glucose. This compound exhibits significant biological activities, including anticoagulation, antiviral properties, and anti-lipemic effects. Its mechanisms involve blocking HIV-1 adsorption to host cells, preventing natural killer (NK) cell-mediated cytotoxicity, and inhibiting instant blood-mediated inflammatory reactions (IBMIR). Dextran sulfate sodium salt (MW 5000) is valuable in research related to immunology, virology, and cardiovascular studies.

ODN 1826 is a class B CpG oligodeoxynucleotide that acts as an agonist for Toll-like receptor 9 (TLR9). It stimulates the production of nitric oxide (NO) and inducible nitric oxide synthase (iNOS), promoting apoptosis and enhancing immune surveillance. This compound is also associated with increased aortic atherosclerotic plaque size and exhibits antitumor activity against various cancer types, including lung cancer, glioma, and melanoma. ODN 1826 is valuable for researching immune response mechanisms and potential cancer therapies.

Afimetoran is a selective and highly bioavailable antagonist of Toll-like receptors 7 and 8 (TLR7/8). It effectively inhibits TLR7/8-mediated activation of the NF-κB signaling pathway and can reverse TLR7-induced resistance to steroid-driven apoptosis in plasmacytoid dendritic cells. This compound is particularly relevant for research into inflammation and autoimmune diseases, including systemic lupus erythematosus.

Agatolimod is a Toll-like receptor 9 (TLR9) agonist and immunomodulator with an EC50 of 180 nM. It activates TLR9 and upregulates TLR6 expression, initiating downstream signaling through IRAK4, IRF5, and IRF7. Agatolimod enhances Th1-type immune responses and promotes the activation of various immune cells, leading to increased antigen presentation, antibody regulation, cytokine secretion, apoptosis, and enhanced cytotoxicity. This compound is relevant for research into COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis.

Britannin is an autophagy inducer and NLRP3 inflammasome inhibitor with an IC50 of 3.630 μM. It exhibits significant anti-inflammatory effects by disrupting the interaction between NLRP3 and NEK7, effectively preventing NLRP3 activation and assembly. Additionally, Britannin shows antitumor properties by inhibiting tumor cell proliferation through interference with the interaction of HIF-1α and Myc, leading to reduced PD-L1 expression and enhanced activity of cytotoxic T lymphocytes. This compound also promotes apoptosis and autophagy in liver cancer cells via activation of ROS-regulated AMPK, making it a valuable tool for research in anti-inflammatory and oncology studies.

Ibuprofen sodium is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 13 μM. This compound demonstrates significant biological activities, including inhibition of cell proliferation, angiogenesis, and induction of apoptosis. As a nonsteroidal anti-inflammatory agent and nitric oxide (NO) donor, ibuprofen sodium is valuable in research areas such as pain, inflammation, infection, immunology, and oncology.

Taurodeoxycholic acid is an anionic bile salt with anti-inflammatory properties, primarily targeting inflammation pathways. It demonstrates significant neuroprotective effects and is utilized in the isolation of membrane proteins, including those from the inner mitochondrial membrane. This compound is valuable for research applications involving membrane biochemistry and neuroinflammation studies.

Taurochenodeoxycholic acid sodium is a bile acid derivative that exhibits anti-inflammatory properties through the modulation of immune responses. This compound has been shown to induce apoptosis and plays a significant role in reducing inflammation. Its biological activities make it a valuable reagent for research applications focused on understanding inflammatory diseases and potential therapeutic strategies.

Kynurenic acid-d5 is a deuterium-labeled analog of kynurenic acid, an endogenous metabolite of tryptophan. It acts as a broad-spectrum antagonist of NMDA and glutamate receptors, as well as the α7 nicotinic acetylcholine receptor. Additionally, kynurenic acid-d5 serves as an agonist for GPR35/CXCR8, making it valuable in studies related to neuropharmacology and neurotransmitter signaling pathways. This stable isotope is ideal for tracing and characterization studies in metabolic research.

MRT199665 is a potent, ATP-competitive inhibitor targeting MARK, SIK, and AMPK pathways, exhibiting IC50 values of 2 nM for MARK1, 10 nM for AMPKα1, and 110 nM for SIK1. This compound induces apoptosis in MEF2C-activated human acute myeloid leukemia (AML) cells by effectively inhibiting the phosphorylation of the SIK substrate CRTC3 at S370. MRT199665 serves as a valuable tool for investigating the roles of MARK, SIK, and AMPK in cellular signaling and cancer biology.

Robinin is a flavonoid that acts as an inhibitor of Toll-like receptors 2 and 4 (TLR2/4), modulating the TGF-β, TLR4/NF-κB, and TLR2-PI3k-AKT signaling pathways. This compound demonstrates significant anti-inflammatory and anti-tumor properties. Additionally, Robinin has been shown to enhance the anti-inflammatory effects of Methotrexate in experimental arthritis models and may mitigate cardiac toxicity induced by Doxorubicin. These attributes make Robinin a valuable reagent for research applications in inflammation and cancer therapy.

Plantainoside D is a phenylethanoid glycoside that functions primarily as an inhibitor of IKK-β, with additional inhibitory effects on angiotensin-converting enzyme (ACE) and protein kinase C (PKC). It exhibits significant biological activities, including the reduction of glutamate release in the rat cerebral cortex, alleviating cell apoptosis through the inhibition of reactive oxygen species (ROS) and NF-κB activation. Additionally, Plantainoside D has been shown to improve outcomes in acute lung injury induced by sepsis via modulation of the Sirt3/NLRP3 signaling pathway. This compound is applicable in studies of neuroprotection, antioxidant activity, anti-inflammatory responses, and antihypertensive effects.

Nangibotide is a synthetic peptide that serves as a TREM-1 receptor inhibitor. By inhibiting NF-κB and NLRP3 inflammasome activation, Nangibotide effectively reduces the release of pro-inflammatory cytokines such as IL-1β and IL-8 and mitigates apoptosis. This reagent is valuable for research applications related to excessive inflammatory responses, including studies on myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure. Additionally, Nangibotide offers protective effects on tissues, such as the liver and lung, during inflammatory conditions.

CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, exhibiting an IC50 of 0.63 µM. This compound demonstrates significant anti-inflammatory and antioxidant properties by activating the Nrf2-dependent pathway and inhibiting the NF-κB-related inflammatory response. CPUY192018 is ideal for research applications focused on inflammation-related diseases and the modulation of oxidative stress.

Lonicerin, also known as Veronicastroside, is a flavonoid recognized for its anti-inflammatory properties. It inhibits xanthine oxidase with an IC50 of 37.4 µg/mL and suppresses alginate secretion protein (AlgE). Lonicerin demonstrates a broad spectrum of biological activities, including antimicrobial effects against Pseudomonas aeruginosa and Candida albicans, as well as antioxidant and neuroprotective effects. Its diverse applications make it valuable in research focused on inflammation, infection, and oxidative stress.

Hederacoside C is a potent anti-inflammatory agent that targets the MAPK/NF-κB signaling pathway. It exerts its biological activity by inhibiting the activation of this pathway, resulting in a reduction of inflammation. In addition to its anti-inflammatory properties, Hederacoside C also demonstrates antibacterial activity, making it a valuable compound for research applications focused on inflammatory diseases and infections.

Muzastotug is a humanized immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). It functions as both an immunostimulant and an antineoplastic agent. This antibody is designed to enhance the immune system's response against tumor cells by inhibiting CTLA-4, a protein that downregulates the immune response.

Vilastobart is a human IgG1 κ monoclonal antibody targeting CTLA-4. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Sovipostobart is a human monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CTLA-4 with a cleavable prodomain. It functions as both an immunostimulant and an antineoplastic agent. This biologic is designed to modulate the immune system by inhibiting CTLA-4, a protein that downregulates immune responses, thereby enhancing the body's antitumor activity. Sovipostobart is applicable in the study of immune checkpoint blockade therapies and is relevant for research focused on cancer immunotherapy.

Botensilimab (AGEN 1181) is a human monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4), serving as both an innate and adaptive immune activator. This biologic is specifically designed for use in cancer research, where it facilitates the study of immune checkpoint blockade and its effects on tumor immunity.

Solasonine is a naturally occurring steroidal glycoalkaloid isolated from *Solanum melongena* (eggplant), known for its anti-infective, anticancer, and neurogenesis-promoting properties. It acts as a ferroptosis inducer by disrupting the glutathione redox system through inhibition of glutathione peroxidase 4 (GPX4). By promoting ferroptotic cell death in hepatocellular carcinoma (HCC) cells, Solasonine serves as a valuable compound for investigating ferroptosis mechanisms and developing novel anticancer strategies.

RMC-5127 is an orally active, brain-penetrant, mutant-selective tri-complex inhibitor targeting RASG12V. It non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages active RASG12V to create a high-affinity tri-complex, thereby sterically blocking RAS-effector interactions. RMC-5127 inhibits RAS signaling in KRASG12V-mutant cancer cells, suppressing proliferation and inducing apoptosis. It holds promise for the study of RAS-mutant cancers, including non-small cell lung cancer.

Isofraxidin is a coumarin compound derived from *Acanthopanax senticosus* that exhibits anti-invasive and anti-inflammatory properties. It inhibits MMP-7 expression and suppresses cell invasion in human hepatoma cells by reducing ERK1/2 phosphorylation. Isofraxidin also downregulates the expression of iNOS and COX-2 and inhibits the formation of the TLR4/myeloid differentiation protein-2 (MD-2) complex.

JPE-1375 is a complement C5a receptor 1 (C5aR1) antagonist that effectively inhibits polymorphonuclear leukocyte mobilization with an EC₅₀ of 6.9 µM and reduces TNF levels with an EC₅₀ of 4.5 µM in mice. It is suitable for research in autoimmune and inflammatory diseases.

EG01377 dihydrochloride is a potent, bioavailable, and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM and IC₅₀ values of 609 nM for both NRP1-a1 and NRP1-b1 domains. It exhibits antiangiogenic, antimigratory, and antitumor activities.

Perforin-IN-2 (Compound 1) is a perforin inhibitor that blocks perforin-mediated cell lysis. It has potential to reduce graft rejection in the context of allogeneic bone marrow or stem cell transplantation.

Lipoteichoic acid is an orally active compound with anti-inflammatory and antitumor properties. It is a key immune molecule found in Gram-positive bacteria that activates the complement system by upregulating C3 and inhibiting CD55. Lipoteichoic acid modulates macrophage autophagy via the PI3K/Akt/mTOR pathway, induces lung injury in mouse models, and inhibits melanin production.

Vemircopan (ALXN2050) is an orally active inhibitor of complement factor D (FD). It is being investigated for the treatment of complement-mediated diseases, including myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria (PNH).

W-54011 is a potent, orally active, non-peptide antagonist of the C5a receptor. It inhibits the binding of \[¹²⁵I]-labeled C5a to human neutrophils with a Kᵢ of 2.2 nM. W-54011 also suppresses C5a-induced intracellular Ca²⁺ mobilization, chemotaxis, and reactive oxygen species (ROS) generation in human neutrophils, with IC₅₀ values of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.